Header Logo

Connection

James Hocker to Humans

This is a "connection" page, showing publications James Hocker has written about Humans.
Connection Strength

0.325
  1. Serum discrimination and phenotype assessment of coronary artery disease patents with and without type 2 diabetes prior to coronary artery bypass graft surgery. PLoS One. 2020; 15(8):e0234539.
    View in: PubMed
    Score: 0.041
  2. Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Invest. 2017 Oct 21; 35(9):573-585.
    View in: PubMed
    Score: 0.033
  3. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Cancer Lett. 2015 Apr 10; 359(2):314-24.
    View in: PubMed
    Score: 0.028
  4. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling. Cancer Invest. 2014 May; 32(4):136-43.
    View in: PubMed
    Score: 0.026
  5. Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation. Int J Cancer. 2013 Dec 01; 133(11):2662-71.
    View in: PubMed
    Score: 0.025
  6. Discriminating experimental Listeria monocytogenes infections in mice using serum profiling. Appl Microbiol Biotechnol. 2012 Nov; 96(4):1049-58.
    View in: PubMed
    Score: 0.024
  7. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
    View in: PubMed
    Score: 0.022
  8. Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling. Cancer Invest. 2012 Feb; 30(2):180-8.
    View in: PubMed
    Score: 0.022
  9. Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer. 2011 Nov; 74(2):206-11.
    View in: PubMed
    Score: 0.021
  10. Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling. Cancer Invest. 2011 Feb; 29(2):173-9.
    View in: PubMed
    Score: 0.021
  11. Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. Int J Mol Sci. 2022 Mar 18; 23(6).
    View in: PubMed
    Score: 0.011
  12. Distinguishing patients with idiopathic epilepsy from solitary cysticercus granuloma epilepsy and biochemical phenotype assessment using a serum biomolecule profiling platform. PLoS One. 2020; 15(8):e0237064.
    View in: PubMed
    Score: 0.010
  13. Distinguishing and phenotype monitoring of traumatic brain injury and post-concussion syndrome including chronic migraine in serum of Iraq and Afghanistan war veterans. PLoS One. 2019; 14(4):e0215762.
    View in: PubMed
    Score: 0.009
  14. Distinguishing neurocysticercosis epilepsy from epilepsy of unknown etiology using a minimal serum mass profiling platform. Exp Parasitol. 2018 Sep; 192:98-107.
    View in: PubMed
    Score: 0.009
  15. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One. 2015; 10(2):e0118933.
    View in: PubMed
    Score: 0.007
  16. Mechanisms of inhibition of zinc-finger transcription factors by selenium compounds ebselen and selenite. J Inorg Biochem. 2009 Mar; 103(3):419-26.
    View in: PubMed
    Score: 0.005
  17. Biomarker identification in human pancreatic cancer sera. Pancreas. 2008 Jan; 36(1):61-9.
    View in: PubMed
    Score: 0.004
  18. Mechanisms of aurothiomalate-Cys2His2 zinc finger interactions. Chem Res Toxicol. 2005 Dec; 18(12):1943-54.
    View in: PubMed
    Score: 0.004
  19. cDNA cloning, DNA binding, and evolution of mammalian transcription factor IIIA. Gene. 2002 Jan 09; 282(1-2):43-52.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.